US And Canada

Yale-linked Vera has rebranded from Trucode Gene Repair and will use the money to move towards clinical trials.

Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.

Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.

Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.

Novo and GV participated in a round that lifted the Harvard, Broad Institute and Penn-linked heart disease drug developer's overall funding to more than $215m.

Christine Karslake is set to lead UChicago’s Polsky Science Ventures unit and will be tasked with setting up a deep tech-focused accelerator.

Indiana University is among four US institutions selected by the US Department of Defense's open national security innovation programme for a new accelerator targeting applied research spinouts.

University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.